Ge Long Hui A P P·2025-10-15 02:57Group 1 - The core viewpoint of the report is that JD Health is expected to maintain a strong performance in Q3 2023, with an anticipated revenue growth rate of approximately 25% year-on-year [1] - The company is projected to achieve a non-IFRS net profit growth at a double-digit level year-on-year for Q3 2023, driven by ongoing investments in its omnichannel system [1] - Due to better-than-expected contributions from pharmaceutical partnerships and manageable future investments, the profit forecasts for JD Health's non-IFRS net profit for 2025 and 2026 have been raised by 5% and 4% respectively, reaching 5.72 billion and 6.31 billion yuan [1] Group 2 - The ongoing development of the omnichannel system is expected to enhance the company's competitiveness, leading to an upward adjustment of the target price by 11.2% to 67.4 HKD [1] - The report maintains an "outperform" rating for JD Health, indicating confidence in the company's ability to sustain strong growth in its fundamentals for Q3 [1]